Composite materials, specifically to materials used in medicine, in particular, in ophthalmology for the manufacturing of optical ophthalmic implants, mainly intraocular lenses (IOL), intended for vision correction after cataract removal. The polymerization rate of the material is controlled in order to eliminate defects in the ophthalmic implant profile, control the geometric dimensions, reduce the finished product glistening while keeping optimal physical and mechanical properties. The material for the manufacturing of ophthalmic implants by photo-polymerization method includes: a) 60-70 wt. % oligomer of urethanedi(meth)acrylate with terminal (meth)acrylate fragments; b) 20-40 wt. % of (meth)acrylate monomers with aromatic substituents in the side chain; c) 5-25 wt. % of (meth)acrylate monomers with aliphatic branched substituents in the side chain; d) at least 0.2 wt. % of a UV-absorbing component; e) 0.1 to 1 wt. % of photopolymerization initiator; and f) 0.005 to 0.5 wt. % of a radical polymerization inhibitor.

The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.

The invention is directed to topical drug vehicle platform compositions for ophthalmological and dermatological use. These compositions comprise a means to sequester tears and an ophthalmological drug. The invention is further directed to methods of treating a spectrum of ocular surface disease epitheliopathies including but not limited to dry eye in a human or mammal. The invention is further directed to contact lenses, punctum plugs, pellets or any other device used to deliver drugs to the surface of the eye, coated or infused with compositions of the invention.

A punctum plug or lacrimal insert is constructed of a monolithic material, such that the punctum plug is configured to turn approximately 90 degrees upon insertion into a canaliculus of an eye. The punctum plug or lacrimal insert may include high-molecular-weight polysaccharide and added plasticizers.

Methods of reducing oxidative damage to an eye of a subject are provided. Aspects of the method include intravitreal injection an antioxidant composition consisting essentially of a non-reducing sugar or a hydrate thereof. In some embodiments, the non-reducing sugar is trehalose. The methods can further include surgical removal of at least a portion of the subject's vitreous humor during a vitrectomy. Also provided are ophthalmic compositions, kits and pre-loaded injection devices for use in vitrectomy surgery which find use in the subject methods.

The present embodiments provide compositions, methods and kits for the treatment of ocular conditions or maladies affecting the back of the eye, e.g., the retina.

Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.

Provided herein are sustained-release biodegradable ocular hydrogel implants which are useful in the treatment of certain ocular conditions.

The present disclosure provides an ophthalmic article. The ophthalmic article may comprise a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer. The ophthalmic article may also comprise an active agent or a diagnostic agent. The ophthalmic article may be configured to associate to a haptic of an intraocular lens (IOL).

A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.